Nanjing Hicin Pharmaceutical Co., Ltd.

Equities

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-07-01 EDT 5-day change 1st Jan Change
15.67 CNY +2.08% Intraday chart for Nanjing Hicin Pharmaceutical Co., Ltd. +4.75% -32.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hicin Pharmaceutical Gets Registration Certificate for Tenofovir Alafenamide Fumarate Tablet MT
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 18 June 2024 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. cancelled the transaction announced on June 10, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes CI
Nanjing Hicin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 400 million in funding CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022 CI
Nanjing Hicin Pharmaceutical Approves Profit Distribution for 2021 CI
Nanjing Hicin Pharmaceutical Proposes Profit Distribution for 2021 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 13, 2021 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2020 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces 2019 Final Distribution Plan to Be Implemented (A Shares), Payable on May 14, 2020 CI
Chart Nanjing Hicin Pharmaceutical Co., Ltd.
More charts
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300584 Stock
  4. News Nanjing Hicin Pharmaceutical Co., Ltd.
  5. Hicin Pharmaceutical Gets Registration Certificate for Tenofovir Alafenamide Fumarate Tablet